Dear Donors and Friends of Concern Foundation for cancer research:

These days when so many things are changing all around us it’s important that you know that Concern Foundation remains steadfast and committed to its original mission. With a clear direction and focus, Concern has one goal: to provide salary support to further the careers of gifted young cancer researchers and put an end to all cancers in our lifetime. We strongly believe that with the support of our donors and the precision by which our Scientific Review Committee evaluates each grant proposal, we remain on the right path. Concern has been at the forefront of supporting basic laboratory science focused on the body’s natural immune system and sustaining cancer research scientists since 1968, and we will continue to do all that we can to further the quest to one day conquer this disease.

Cancer remains a serious problem and a “concern” for everyone. We have learned over time and through research that cancer is not a single disease, but rather hundreds of different diseases. For every type of cancer, there appears to be multiple genetic pathways through which cancer can develop. Even within a single organ, cancer can adopt a variety of forms, and this is the reason cancer has become such a difficult disease to conquer. Science has found that even the current treatment options that have been discovered to work against one type of cancer in certain patients or organs may be ineffective in the same organ of another patient. So while today many cancer patients are winning their own personal battle with this disease and going on to live long and healthy lives, others are not so fortunate; and that is why our commitment remains steadfast to do all we can for as long as necessary.

Our annual report gives us an opportunity to share and reflect on some of our past accomplishments by our cancer researchers and show just how far they have come thanks to your support in the fight against cancer. The independent audited financial report also will give you some insight to evaluate how efficient we are in putting your donations to the microscope without wasteful spending on overhead. Concern funded researchers have been quite productive with your dollars and we are no longer just an organization that depends on its signature Block Party as its primary means of raising funds. The growth of our organization and the accomplishments of our researchers are quite impressive; however we all know that there is still a long road ahead of us in unlocking the secrets about cancer and reaching further into our community to raise all of the necessary funds to accomplish our mission.

As President of Concern Foundation, I am proud to present this annual report reflecting our financial position and to share with you not only some of the discoveries in cancer research being done by the Concern supported cancer research scientists, but some of the new ways we are raising funds through our community partnerships, by expanding our calendar of events and our continued outreach to a new generation of givers through our Concern 2 gang.

I hope that you remain inspired and committed to Concern Foundation after reading through the information contained in this annual report. We continue to work hard to keep our administrative overhead as low as possible so that we can grant more of your dollars directly to the researchers that need it the most.

Sincerely,

Derek Alpert
President
WHAT
Concern Foundation’s mission is to further the careers of gifted young cancer researchers (Assistant Professor or equivalent) whose work shows great promise, but may not be sufficiently advanced enough in their careers to justify major funding from the government or other larger funding sources. We focus on funding innovative minds that have a slightly different perspective in attempting to solve the mystery of cancer.

WHY
“We have reached the point of diminishing returns with the available cancer therapies...it’s no longer acceptable in the 21st century to deliver more chemotherapy or radiation. New, novel therapies are necessary.” Scientific Review Committee Member, Laurence Cooper, perhaps said it best when he stated the importance of providing start up grants to young investigators. We believe that a unique approach to looking at cancer will continue to fuel progress and effective therapies in the treatment of cancer. For 43 years, Concern Foundation has made it possible to transform new ideas from the mind of a researcher into fruitful innovations in cancer research.

HOW
New grant proposals are accepted every two years and undergo a rigorous peer review process. Potential applicants are pre-screened with a Letter of Intent, which ensures that only qualified investigators complete the thorough and detailed grant application. Each application is then administratively reviewed. A primary and secondary review follows by Concern Foundation’s Scientific Review Committee. Those applications that advance through these stringent levels are then discussed in further detail at the biennial Scientific Review Committee meeting.

Concern Foundation strives to recruit a cross-section of new and established cancer researchers who comprise our renowned Scientific Review Committee. These exceptional men and women guide our grant review process and help us select the top researchers from a competitive pool of applicants.

Each grant recipient is awarded a $50,000 grant. Provided that sufficient progress is achieved in the first year, Concern awards a second year grant of $50,000. It is the hope of the foundation that after two years of funding, Concern-sponsored researchers go on to publish their findings in major journals, obtain larger awards to further their work, and advance their positions at respected institutions around the United States and abroad.
It is an honor to be funded by the Concern Foundation, particularly considering that I am a young investigator starting my independent career in Spain. I am very grateful to the Concern Foundation for extending its support to researchers working outside the US. Advances in cancer research may come from laboratories localized in different countries. The more investigators working in the field, the more we can advance our fight against cancer.

The transition from the bench to the office is always a difficult one. Being a principal investigator is a multitasking job with several responsibilities including getting competitive funding. Although the situation for young investigators in Spain has improved in recent years, it is particularly difficult to get funds to hire personal, including postdoctoral scientists, technicians, and even PhD students. Research is a team work and a good PI cannot succeed without a qualified team. The other challenge is the limited number of sources for funding available in Spain. The government only funds one project (equivalent to the NIH grants) independently of how successful the group may be. In addition, very few private foundations offer competitive grants and the funds granted by these are extremely low. The situation is even harder for young investigators, making more challenging the transition to independence and consolidation. For this reason, the support I received from the concern foundation has been of enormous value; it has allowed hiring a postdoctoral scientist and getting important materials for the laboratory.

Current therapies for breast cancer are in many cases not effective because of intrinsic or acquired resistance, particularly once the tumor has disseminated and invaded other organs. Thus, it is essential to identify novel therapeutic targets. We have demonstrated that RANK/RANKL pathway promotes mammary tumorigenesis and metastasis in mice and it is the main mediator of the protumorigenic role of progesterone in the mouse mammary gland. Our current line of research aims to understand the mechanism by which RANK promotes mammary tumorigenesis, to characterize the cooperation of RANKL with other signaling pathways with clinical relevance, such as BRCA1 and Her2, and to evaluate the activation of RANKL signaling in breast cancer patients. RANKL inhibition is already indicated for the treatment of bone metastasis; our results will contribute to evaluate therapeutic applications in primary breast cancer.

We are a young group, committed to our line of research, and we believe we can contribute to increasing the current knowledge in breast cancer and impact the clinical practice. It is rewarding to feel that an organization such as Concern Foundation, trusts our project and supports our research.
2010-2012 CONQUER CANCER NOW RECIPIENTS

**PEDIATRIC CANCER - Neuroblastoma**
Shahab Asgharzadeh, M.D.
Childrens Hospital Los Angeles
Los Angeles, CA
www.chla.org

**BRAIN CANCER**
Steven Bensinger, V.M.D, Ph.D.
University of California, Los Angeles
Los Angeles, CA
www.ucla.edu

**CANCER GENETICS**
Patricia Dahia, M.D., Ph.D.
UT Health Science Center at San Antonio
San Antonio, TX
www.uthscsa.edu

**BREAST CANCER**
Andrea Dorfleutner, Ph.D.
Northwestern University
Chicago, IL
www.northwestern.edu

**BRAIN CANCER**
Candelaria Gomez-Manzano, M.D.
University of Texas M.D. Anderson
Houston, TX
www.mdanderson.org

**BREAST CANCER**
Eva Gonzalez-Suarez, Ph.D.
Funded by The Save the Tatas Foundation
Bellvitge Institute for Biomedical Research
Barcelona, Spain
www.pebc.cat
www.idibell.cat

**CANCER GENETICS**
Geraldine Guasch, Ph.D.
Childrens Hospital Medical Center
Cincinnati, OH
www.cincinnatichildrens.org

**CANCER VISUALIZATION TOOLS**
Zeynep Gumus, Ph.D.
Joan & Sanford I. Weill Medical College of Cornell University
New York, NY
www.med.cornell.edu

**PROSTATE CANCER**
Li Jia, Ph.D.
Washington University in St. Louis
St. Louis, MO
www.wustl.edu

**PEDIATRIC CANCER - Leukemia**
Yong-Mi Kim, Ph.D., M.D., M.P.H.
Childrens Hospital Los Angeles
Los Angeles, CA
www.chla.org

**LEUKEMIA**
Ya-Huei Kuo, Ph.D.
Beckman Research Institute of the City of Hope
Duarte, CA
www.cityofhope.org

**LEUKEMIA**
Richard Maser, Ph.D.
The Jackson Laboratory
Bar Harbor, ME
www.jax.org

**LYMPHOMA**
Nami McCarty, Ph.D.
UT Health Science Center at Houston
Houston, TX
www.uthouston.edu

**PROSTATE CANCER**
Mari Shinohara, Ph.D.
Duke University Medical Center
Durham, NC
www.dukehealth.edu

**PEDIATRIC CANCER GENETICS**
Vera Tarakanova, Ph.D.
Medical College of Wisconsin
Milwaukee, WI
www.mcw.edu
Concern Foundation
Annual Report 2009

The following is a list of the 21 cancer researchers, post doctoral fellows and Ph.D students that are currently working in the laboratories of the Lautenberg Center thanks in whole or in part from the funds provided by Concern Foundation.

**Group Leaders**
Dr. Rami Aqeilin  
Prof. Michal Baniyash  
Prof. Yinon Ben–Neriah  
Prof. Ygal Haupt  
Prof. Ofer Mandelboim  
Prof. David Naor  
Dr. Eli Pikarsky  
Prof. Eitan Yefenof

**Post Doctoral Fellows**
Dr. Lynn Wang  
Dr. Irit Alkalay-Snir

**Ph.D. students**
Ariel Pribuda  
Dikla Lankri  
Elad Horowitz  
Elian Ish Shalom  
Ella Elayada  
Gila Cohen  
Ido Bornstein  
Irit Manaster

Mohammed Abu Adah  
Moshe Biton  
Moshe Sadeh  
Naama Kanerek  
Noah Stanietsky  
Orli Cohen  
Osnat Bertok  
Saleh Kwaled  
Shlomit Kfir Ehrenfeld  
Simona Hafetz-Sela  
Yaara Levav  
Yair Klinger
Concern Foundation’s Ongoing Cancer Research Support at the Karolinska Institute in Stockholm, Sweden under the direction of Professor George Klein, M.D.

Concern Foundation with matching funds from CRI (Cancer Research Institute) are currently supporting 20 cancer research scientists focused on 5 specific areas of cancer research. The following are those specific scientific areas and the researchers that are performing their studies.

**AREA A: EPSTEIN-BARR VIRUS (EBV) AND KAPOSI SARCOMA HERPESVIRUS (HHV-8)**

**Molecular studies of viral latency and transformation:**
- Elena Kashuba
- Surya Pavan
- Suhas Darekar
- Emil Khaibulin
- Liang Wu
- Gyorgy Stuber

**EBV – host cell interactions:**
- Lorand Levente Kis
- Daniel Salamon
- Li Fu Hu

**AREA B: ONCOGENES AND TUMOR SUPPRESSOR GENES**

**Myc activation in tumors:**
- Nikolay Zinin
- Inga Muller

**Discovery and analysis of new suppressor genes on the short arm of human chromosome 3:**
- Stefan Imreh
- Maria Alimova
- Alecia Viklund
- Patricia Rodriguez
- Elvira Grigorieva

**AREA C: TUMOR IMMUNOLOGY**
- Noemi Nagy
- Harsha Madapura
- Anquan Liu

**AREA D: CYTOTOXIC DRUG SENSITIVITY**
- Gyorgy Stuber

**AREA E: INHIBITION OF TUMOR CELL GROWTH BY STROMA CELLS**
- Laszlo Markasz

---

**EBV-** Presence of EBV specific T cell responses in infected humanized mice (mice that have been reconstituted with human immune system). Total splenocyte populations (T and B cells) of EBV infected humanized mice were plated with or without the cell inhibitor cyclosporine A (CsA). After 4 weeks, individual wells were photographed to record the size of the growing clumps representing EBV transformed cells that survived the specific T cell control. Growth of the EBV transformed cells occurred when the T cells were inhibited by CsA (right side of the picture), while these EBV infected B cells did not grow in the presence of T cells (control). This growth pattern proves the existence of EBV specific T cells in the spleen.

**Co-culture** - The non-inhibitory prostate fibroblasts express smooth-muscle actin (GREEN) both when they are cultured alone and when in co-culture with A549-lung carcinoma cells (PINK nuclei). Both cell types are stained with Hoechst (blue nuclei).

---

**Laszlo & Emillie** - George Klein’s and Laszlo Szekely’s group, working on tumor resistance, particularly the inhibitory activity of normal fibroblasts on tumor cells.

**George & Noemi** - George Klein with Noemi Nagy, senior fellow in Eva Klein’s group. The following illustration exemplifies part of her project: EBV
Raising Funds for Cancer Research

The Concern Foundation for Cancer Research held its 36th Annual Block Party on the back lot of Paramount Studios on Saturday, July 10 brought in a well over One Million Dollars, which will go towards the funding for 48 cancer researchers across America and around the world. The evening honored Jim & Ishita Ganguly-Morrison for their commitment toward finding a cure for cancer.

This year’s circus themed block party has become one of the most exceptional “foodie” events in Los Angeles, brought in 11 new restaurants/caterers and beverage suppliers this year making for a total of 63 stations throughout the venue. Other attractions included massages and manicures from LeSpa at Sofitel Hotel Los Angeles, which was booked throughout the night, digital photos sponsored by Hold the Date Events, and donation stations throughout the party where guests could purchase flashing hearts to wear on their lapels that raised an additional $6,000. Also present at the event was Concern’s community partner; the Save the Tatas Foundation, which has committed $50,000 toward Concern’s support of an upcoming breast cancer researchers. Once again, Concern was proud to partner with Los Angeles Magazine for the 6th year in a row to raise awareness and additional support for cancer research.

Musical entertainment was provided by the stellar Tom Nolan Band and DJ Layne who kept things hopping in the area adjacent to the 70 plus table casino. A tremendous silent auction area and live auction brought in some additional revenue to support the cancer research scientists. Clowns, trapeze artists and circus acts throughout the venue kept the over 3,000 guests entertained all night long. The evening’s MC was once again the fantastic Frank Mottek of KNX Newsradio’s Business Hour.

Team Concern debuted as an official charity of the Honda LA Marathon in 2010 as the top fundraiser of all new charities, and the 7th highest fundraising charity overall raising over $60,000. We had nearly 80 participants between the full 26.2 Marathon and the 5k warm-up race around Dodger Stadium. Our participants are more than committed to working together as a team to conquer cancer as we go into 2011 with the fundraising goal of reaching a $100,000.
Universal Studios hosts Annual "Day for the Kids"
Concern’s 22nd Annual “Day for the Kids” at Universal Studios was held on Sunday, October 3rd. Thanks to the generosity of Universal Studios, approximately 300 pediatric cancer patients and their guests spent the day with us, along with over 50 volunteers, completely free of charge. Universal arranged a private Studio Tour tram ride, catered a wonderful lunch for everyone in the Globe Theater, and provided us with front of the line priority passes. The day went seamlessly thanks to the hard work and enthusiasm of all our volunteers.

Concern Celebrates the Holidays at Paramount Studios
December 12, 2010 was a day to remember as Concern Foundation hosted our 23rd Annual Holiday Party at Paramount Studios for pediatric cancer survivors and their families. With over 600 guests and volunteers, there was a sea of smiles as everyone enjoyed a private screening of Mega Mind and a late lunch donated by Fatburger, POPchips and Krispy Kreme Donuts. DJs from Party Layne spun everyone’s favorite tunes while guests danced, struck a pose in LA Photo Party’s mini photo studio, played in the amazing video games truck provided by Videogames2U, had their bodies painted by Island Ink, and decorated cookies. The official Santa to the Stars made a special appearance posing with every guest for photo souvenirs taken and donated by Brian Kramer Photography. Not a family went home empty handed as every child left with a big bag of candy and gifts that had been individually selected for each and every one of them.

We are thankful for the support and generosity of our community partners who helped Concern Foundation further our mission to CONquer canCER Now in 2010.
### Financials - YEAR ENDING DEC 31, 2010

**ASSETS**

**Assets**

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$360,085</td>
</tr>
<tr>
<td>Investments</td>
<td>2,904,682</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>267,359</td>
</tr>
<tr>
<td>Beneficial interest in charitable remainder trusts</td>
<td>248,042</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>8,781</td>
</tr>
<tr>
<td>Other assets</td>
<td>68,649</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$3,857,598</strong></td>
</tr>
</tbody>
</table>

**LIABILITIES AND NET ASSETS**

**Liabilities**

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants payable</td>
<td>$287,500</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>38,624</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>267,359</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>593,483</strong></td>
</tr>
</tbody>
</table>

**Commitments**

**Net Assets**

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted - Undesignated</td>
<td>204,100</td>
</tr>
<tr>
<td>Unrestricted - Designated</td>
<td>800,000</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>309,643</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>1,950,372</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>3,264,115</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$3,857,598</strong></td>
</tr>
</tbody>
</table>
### Revenue and support

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>186,316</td>
<td>14.58%</td>
</tr>
<tr>
<td>Special events, net</td>
<td>792,555</td>
<td>62.01%</td>
</tr>
<tr>
<td>Campaign</td>
<td>71,709</td>
<td>5.61%</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>131,429</td>
<td>10.28%</td>
</tr>
<tr>
<td>Trust income</td>
<td>4,261</td>
<td>0.33%</td>
</tr>
<tr>
<td>Partnership income</td>
<td>28,748</td>
<td>2.25%</td>
</tr>
<tr>
<td>Change in value of charitable remainder trusts</td>
<td>20,998</td>
<td>1.64%</td>
</tr>
<tr>
<td>Net unrealized losses on investments</td>
<td>38,874</td>
<td>3.04%</td>
</tr>
<tr>
<td>Membership Net assets released from restrictions</td>
<td>3,200</td>
<td>0.25%</td>
</tr>
<tr>
<td>Reclassification of interest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfaction of temporary restrictions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total revenue and support**: $1,278,090 (100.00%)

### Functional expenses

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>1,209,371</td>
<td>94.62%</td>
</tr>
<tr>
<td>Management and general</td>
<td>109,891</td>
<td>8.60%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>157,393</td>
<td>12.31%</td>
</tr>
</tbody>
</table>

**Total functional expenses**: $1,476,655 (115.54%)

**Change in net assets**: $(198,565) (-15.54%)
CONQUER CANCER NOW!